title: High Variability in the Reported Management of Hepatic Veno-Occlusive Disease in Children after Hematopoietic Stem Cell Transplantation.
abstract: Veno-occlusive disease (VOD) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). Patients with VOD are often critically ill and require close collaboration between transplant physicians and intensivists. We surveyed members of a consortium of pediatric intensive care unit (PICU) and transplant physicians to assess variability in the self-reported approach to the diagnosis and management of VOD. An internet-based self-administered survey was sent to pediatric HSCT and PICU providers from September 2014 to February 2015. The survey contained questions relating to the diagnosis and treatment of VOD. The response rate was 41% of 382 providers surveyed. We found significant variability in the diagnostic and management approaches to VOD in children. Even though ultrasound is not part of the diagnostic criteria, providers reported using reversal of portal venous flow seen on abdominal ultrasound in addition to Seattle criteria (70%) or Baltimore criteria to make the diagnosis of VOD. Almost 40% of respondents did not diagnose VOD in anicteric patients (bilirubin < 2 mg/dL). Most providers (75%) initiated treatment with defibrotide at the time of diagnosis, but 14%, 7%, and 6% of the providers waited for reversal of portal venous flow, renal dysfunction, or pulmonary dysfunction, respectively, to develop before initiating therapy. Only 50% of the providers restricted fluids to 75% of the daily maintenance, whereas 21% did not restrict fluids at all. Albumin with diuretics was used by 95% of respondents. Platelets counts were maintained at 20,000 to 50,000/mm(3) and 10,000 to 20,000/mm(3) by 64% and 20% of the respondents, respectively. Paracentesis was generally initiated in the setting of oliguria or hypoxia, and nearly 50% of the providers used continuous drainage to gravity, whereas the remainder used an intermittent drainage approach. Nearly 73% of the transplant providers used VOD prophylaxis, whereas the remainder did not use any medications for VOD prophylaxis. There was also considerable variation in the management strategies among the transplant and critical care providers. We conclude that there is considerable self-reported variability in the diagnosis and management of VOD in children. The practice variations reported in this study should encourage the development of standard practice guidelines, which will be helpful in improving the outcome of this potentially fatal complication.
authors: Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio.
authors: Micah A
authors: MA
authors: Skeens
authors: Division of Critical Care Medicine, St Jude Children's Research Hospital, Memphis, Tennessee.
authors: Jennifer
authors: J
authors: McArthur
authors: Division of Critical Care Medicine, Dept of Pediatrics, Duke Children's Hospital, Durham, North Carolina.
authors: Ira M
authors: IM
authors: Cheifetz
authors: Pediatric Hematology-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors: Christine
authors: C
authors: Duncan
authors: Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts.
authors: Adrienne G
authors: AG
authors: Randolph
authors: Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio.
authors: Joseph
authors: J
authors: Stanek
authors: Pediatric Hematology-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors: Leslie
authors: L
authors: Lehman
authors: Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio. Electronic address: Rajinder.bajwa@nationwidechildrens.org.
authors: Rajinder
authors: R
authors: Bajwa
mesh_terms: D001826:Body Fluids / Q000378:metabolism; D002648:Child; D003695:Delivery of Health Care / Q000706:statistics & numerical data; D019468:Disease Management; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006504:Hepatic Veno-Occlusive Disease / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D008297:Male; D019152:Paracentesis / Q000379:methods; D010976:Platelet Count; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D011795:Surveys and Questionnaires; D061665:Time-to-Treatment
chemical_list: D004232:Diuretics; D011089:Polydeoxyribonucleotides; C036901:defibrotide
keywords: Management; VOD; Variations in treatment